Galera Therapeutics is a clinical-stage biotech company focused on the development of drugs targeting the oxygen metabolic pathways. The company's lead compounds are small molecule dismutase mimetics which closely mimic the activity of the human superoxide dismutase enzymes.
Net income (Q2, 2020)
EBIT (Q2, 2020)
Market capitalization (20-Nov-2020)
Closing stock price (20-Nov-2020)
|Company Name||Date||Deal Size|
|Galera Therapeutics Australia Pty Ltd|
When was Galera Therapeutics founded?
Galera Therapeutics was founded in 2009.
Who are Galera Therapeutics key executives?
Galera Therapeutics's key executives are J. Mel Sorensen, Robert A. Beardsley and Dennis P. Riley.
How many employees does Galera Therapeutics have?
Galera Therapeutics has 26 employees.
Who are Galera Therapeutics competitors?
Competitors of Galera Therapeutics include VivaBioCell, Abcam and Xcell Biosciences.
Where is Galera Therapeutics headquarters?
Galera Therapeutics headquarters is located at 2 W Liberty Blvd #110, Malvern.
Where are Galera Therapeutics offices?
Galera Therapeutics has an office in Malvern.
How many offices does Galera Therapeutics have?
Galera Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies